A few things to consider!
$MAIA Biotechnology (MAIA.US)$ •The lead asset THIO, is the only direct telomere-targeting agent currently in clinical development
• They Recently published preliminary data from the Phase 2 clinical trial THIO-101 with unprecedented disease control and response rates that outperformed the current standard of care
• A impressive Pipeline of immuno-oncology therapies including NSCLC and multiple hard-to-treat cancers with unmet need
• And dont forget a Second-generation telomere-targeting program![]()
• They Recently published preliminary data from the Phase 2 clinical trial THIO-101 with unprecedented disease control and response rates that outperformed the current standard of care
• A impressive Pipeline of immuno-oncology therapies including NSCLC and multiple hard-to-treat cancers with unmet need
• And dont forget a Second-generation telomere-targeting program
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
